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1. Introduction  
Light chain (AL) amyloidosis is a protein misfolding disease characterized by the abnormal 
proliferation of monoclonal plasma cells that secrete free immunoglobulin light chains (LC) 
into circulation. These LCs misfold and aggregate as amyloid fibrils in vital organs. The 
process of amyloid formation causes organ failure, although the exact mechanism is 
unknown. The most frequently affected organs are the kidneys, heart, liver and peripheral 
nerves. AL amyloidosis is a devastating disease with a median survival of 12-40 months 
(Kumar et al., 2011; Wechalekar et al., 2008). The incidence of AL is 9 per million per year in 
the US, comparable to the incidence of Hodgkin’s Lymphoma. Current treatments are harsh 
and not curative (chemotherapy and autologous stem cell transplantation), targeting the 
plasma cells producing the protein. There is currently no treatment that targets the 
misfolding process or the amyloid fibrils.   
This chapter will discuss the latest developments in our understanding of the molecular 
mechanisms of AL amyloidosis including the role of mutations, cellular microenvironment, 
dimerization structures, different species populated in AL amyloid fibril formation, and 
light chain-associated cell and tissue toxicity. We will describe the challenges facing AL 
amyloidosis researchers to develop effective animal models of the disease and to find the 
best therapeutic strategies to treat this complex, devastating disease. 
2. Light chain (AL) amyloidosis – Role of the protein in disease 
A LC is composed of an N-terminal variable domain (VL) and a C-terminal constant domain 
(CL). The VLs are not uniformly variable throughout their lengths. Three small regions, the 
hypervariable regions or complementarity determining regions (CDR), show much more 
variability than the rest of the domain. These regions vary both in size and in sequence 
among different VL germline isotypes; they determine the specificity of the antigen-antibody 
interactions. The remaining parts of the VL, four framework regions (FRs), have quite similar 
amino acid sequences. The overall structure of the VL is an immunoglobulin fold with 9 -
strands (A, B, C, C’, C”, D, E, F, and G) packed tightly against each other in two antiparallel 
 sheets joined together by a disulfide bridge in a form of a Greek key -barrel. The N- and 
C- termini strands (A and G, respectively) are parallel (Branden & Tooze, 1999). The CDRs 
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form three loops between amino acids 24-34, 50-56 and 89-95 that contain the sequence that 
will recognize the antigen.  
 
 
Fig. 1. (A) Immunoglobulin (IgG) structure showing heterotetramer of two light chains and 
two heavy chains linked by disulfide bonds (B) Schematic representation of a LC showing 
complementarity determining regions (CDR) and framework regions (FR) (C) VL structure 
showing CDR regions, β strands C, C’, F, and G involved in heavy/light chain interface, and 
N and C termini (β strands A and G, respectively). 
Immunoglobulin quaternary structure consists of a heterotetramer formed by the LC and 
the heavy chain (HC) linked together via disulfide bonds. The LC VL domain interacts with 
the HC variable domain through -strands C, C’, F and G.  The source of sequence 
variability in LCs comes from combinatorial pairing of the V genes (discussed below) and 
the J genes (corresponding to strand G or FR4), making it possible to generate about 3000 
different LC sequences. In addition, somatic mutations improve the antibody affinity for the 
antigen, leading to further sequence variation. LCs are secreted and are found in circulation 
and are sometimes referred to as Bence-Jones proteins. Heavy chains are unable to be 
secreted alone, so they are always present as part of an intact immunoglobulin molecule as 
shown in Figure 1. 
There are 40 kappa and 33 lambda germline genes available to form a LC variable domain. 
In AL amyloidosis, there is an overrepresentation of specific germline genes: I, 1, II, III, 
and VI (Poshusta et al., 2009). The process of somatic hypermutation adds to the 
complexity of AL amyloidosis because it means that each patient possesses a unique 
amyloidogenic protein: a combination of different germline genes and different somatic 
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mutations. These protein sequence differences could result in different propensities to form 
amyloid fibrils, and may be involved in the different organ involvement found in different 
AL patients as well as the different degrees of severity of the disease.  
Most of the biochemical and biophysical studies reported in the literature have been 
conducted using the variable domain of AL proteins (Baden et al., 2009). This stems from the 
fact that variable domain fragments were found in AL amyloid deposits and for 20 years it 
was thought that the protein underwent limited proteolysis before or after becoming part of 
the amyloid fibril. However, a recent report describing the laser micro-dissection of amyloid 
deposits from biopsied tissue followed by mass spectrometry analysis determined that the 
full length immunoglobulin light chain is present in the amyloid deposits of these patients 
(Vrana et al., 2009), contradicting the previous assumption that only light chain variable 
domains are found in amyloid deposits. 
2.1 What contributes to the amyloidogenicity of immunoglobulin light chains? 
It is generally accepted that LCs from AL patients are prone to aggregation due to a number 
of factors: certain germline sequences are overrepresented and may be intrinsically more 
prone to aggregation (see section 2.1.1.); somatic mutations destabilize the protein and may 
promote conformations that are more favorable for amyloidogenesis (see section 2.1.2) or 
decrease thermodynamic stability (see section 2.1.3). Finally, the presence of co-factors and 
the cellular environment play an important role (section 2.1.4). 
2.1.1 Sequence determinants of amyloidogenicity 
In AL amyloidosis,  is overrepresented (/=3:1) as compared to healthy individuals or 
multiple myeloma (MM, non amyloidogenic control)  patients (/=1:2), especially the  VI 
subtype (Kyle & Gertz, 1995).  In addition, VL germline donor gene usage in AL is biased 
(Abraham et al., 2003; Comenzo et al., 2001; Prokaeva et al., 2007).  The Comenzo, Abraham 
and Prokaeva studies agree that AL VL germline donor gene usage comprises VI, VII, 
VIII, V VI, V I, while there are slight differences in the sample size, sample selection and 
the frequency of use of each germline donor gene in each study. Comenzo and co-workers 
demonstrated that 30% of AL VL genes used V VI 6a germline donor (Comenzo et al., 
2001).   Abraham and co-workers found that most  patients selected for their study used the 
V I subgroup (77%) (Abraham et al., 2003); a similar observation was made by Prokaeva 
and co-workers (Prokaeva et al., 2007).  
To determine if the germline sequences are prone to generating inherently more 
amyloidogenic AL proteins, two studies tested  and  germline proteins.  Baden et al. 
compared AL-09, an amyloidogenic protein that has 7 somatic mutations, to its germline 
protein I O18/O8 (Baden et al., 2008a). The germline protein was more thermodynamically 
stable than its amyloidogenic counterpart, and although it was able to form fibrils, its fibril 
formation kinetics were significantly slower than AL-09. Additionally, fibril formation of AL 
protein BIF and MM protein GAL (also of the I O18/O8 germline) was compared at 37°C, 
but only BIF formed fibrils (Kim et al., 2000). 
Because the 6a germline is expressed almost exclusively in AL patients (it is one of the last 
germline genes screened in the process of selection) and is not expressed in the normal LC 
repertoire (Abraham et al., 2003; Comenzo et al., 2001; Prokaeva et al., 2007), del Pozo 
Yauner et al. hypothesized that this germline would be as unstable as AL proteins.  
However, experiments revealed that the 6a germline protein was more stable than Wil, an 
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amyloidogenic protein from that germline with 11 somatic mutations (Del Pozo Yauner et 
al., 2008).  The 6a germline also had significantly slower fibril formation kinetics than Wil.   
When compared to AL-09 and I O18/O8, Wil and 6a demonstrated a comparable increase 
in stability, but faster fibril formation kinetics (14 hours for 6a compared to 216 hours for I 
O18/O8 at 37°C). Additionally, 6a was able to form fibrils in the absence of seeds, while I 
O18/O8 required seeds for fibril formation.  This may indicate an increase in fibrillogenic 
propensity for 6a germline proteins.  More studies are necessary to verify that AL-prone 
germline sequences are more amyloidogenic than normal Ig repertoire germline sequences. 
The mutational diversity among AL proteins has been well documented. Several studies 
have compared amino acid sequences of AL proteins, searching for common mutations or 
mutational regions.  In an analysis of 121 I light chains (37 of which were amyloidogenic), 
Stevens found four structural features that render a LC protein more likely to be 
amyloidogenic (Stevens, 2000).  All of these involved loss or gain of certain residues, 
including a mutation that introduces a glycosylation site, mutations of Arg61 or Ile27b and 
mutations of Pro residues in -turns.   
A more recent analysis of 141  and AL light chain sequences catalogued the non-
conservative mutations in these proteins and modeled their positions onto known LC 
structures to correlate structural regions (-strands or loops) with potentially destabilizing 
mutations (Poshusta et al., 2009).  This study confirmed that the total number of non-
conservative mutations may be less important than their location as an amyloidogenic 
determinant for LC proteins.  Additionally, the patients’ free light chain levels, an indicator 
of disease progression (Dispenzieri et al., 2008), were also assessed in a subset of the 
analyzed protein sequences. A correlation between non-conservative mutations in certain 
regions and free light chain (FLC) levels was revealed, suggesting that patients with initial 
low FLC levels acquired mutations in their LCs that rendered these proteins to be more 
amyloidogenic than LCs from patients with higher FLC levels.  Analyzing the location of 
these mutations could further advance understanding of the mechanisms of amyloid 
formation and lead to a prognostic factor for AL disease progression. 
2.1.2 Structural determinants of amyloidogenicity in light chain proteins 
Structural studies have shown that most variable domains from AL amyloidosis patients 
crystallize as monomers or dimers with the expected antiparallel -sheet 
immunoglobulin fold. The dimer observed is homologous to the conformation occurring 
between light and heavy chains in immunoglobulin molecules. The germline I O18/O8 
crystallizes as a canonical dimer while the amyloidogenic protein AL-09  adopts an 
altered dimer with a 90° rotation with respect to the canonical dimer structure (Baden et 
al., 2008a). Restorative mutational analysis showed that a single mutation in AL-09 (AL-
09 H87Y) stabilized the protein, delayed amyloid formation, and changed its 
conformation from the altered dimer to the canonical dimer interface (Baden et al., 
2008b). We have recently reported that the reciprocal mutant I Y87H, in which we 
mutated the germline residue towards the residue found in AL-09, crystallized as a 
canonical dimer. However, using solution Nuclear Magnetic Resonance (NMR) 
spectroscopy, we showed that this protein adopts a different dimer interface rotated 180° 
from the canonical dimer interface and 90° from the AL-09 altered dimer interface 
(Peterson et al., 2010). The different dimer structures could be compared to the hands on 
a clock moving in intervals of 90° (Figure 2).  
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Fig. 2. Overlay of three different dimer orientations found in crystal structures of I O18/O8, 
AL-09, and NMR structure of κI Y87H. (Figure adapted from (Peterson et al., 2010, Fig. 4), with 
permission of Elsevier. Copyright © 2010.) 
Sequence alignments of the variable domains of 50  and 91  AL light chains revealed that 
non-conservative mutations on the dimer interface, especially Histidine mutations, are very 
common in AL proteins (Poshusta et al., 2009). Taken together with our structural analysis 
of AL-09, AL-09 H87Y and I Y87H, our results suggest that dynamic dimerization could 
occur frequently in AL proteins.  Our structural studies show that light chains are able to 
dimerize in different conformations; the residues in the dimer interface determine whether 
or not a dimer conformation will be favored or if the numerous interfaces will be populated 
at the same time. 
2.1.3 Thermodynamic stability as a factor determining amyloidogenicity 
Studies using variable domain proteins from AL patients have shown that mutations in the 
variable domain that reduce the thermodynamic stability are more prone to form amyloid 
fibrils (Hurle et al., 1994; Stevens et al., 1995; Wetzel, 1997). In an analysis linking mutations 
and stability, Hurle et al. analyzed 36 sequences (18  and 18 ) in search of rare amino acid 
replacements that occurred in structurally significant regions of the proteins (Hurle et al., 
1994).  They then constructed single-point mutants incorporating the rare residues into a 
non-amyloidogenic Bence Jones LC protein to determine whether the amino acids 
destabilized the protein significantly enough to induce unfolding.  Four of the six mutations 
were destabilizing, leading to the conclusion that some mutations are involved in 
amyloidogenicity.  
To determine if a single mutation is enough to render a protein amyloidogenic, Davis et al. 
studied AL protein SMA and MM protein LEN.  Only eight residues differ between these 
two proteins, and each SMA mutation was introduced into LEN to assess the individual 
effects on fibrillogenesis.  Of the mutations tested only P40L, located in a loop region, was 
able to form Thioflavine T (ThT) positive fibrils in unseeded reactions (Davis 2000).  
Although stability data were not reported for these mutants, it is likely that the P40L mutant 
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was less stable than wild-type LEN because Pro40 (very favorable for loops and turns) is 
conserved among 98% of all  and  germline sequences.  
In vitro fibril formation studies have revealed that AL proteins form fibrils under a variety of 
solution conditions with varying kinetics and morphology of fibrils. AL-09 is unique 
because it forms amyloid fibrils with very similar kinetics across a wide variety of solution 
conditions (Martin & Ramirez-Alvarado, 2010). Additionally, AL-09’s fibril formation 
kinetics are significantly faster than other AL proteins. We propose that the altered dimer 
interface populated by AL-09 facilitates the initial misfolding events that trigger amyloid 
formation, while the other proteins require stochastic conformational fluctuations to 
populate the appropriate misfolded intermediate that leads the amyloid formation reaction. 
Incubation of light chains from both IV amyloidosis and multiple myeloma patients have 
shown that amyloid formation is enhanced at low pH while amorphous aggregation 
occurred around neutral pH; all of these reactions populated different partially folded 
intermediates (Ionescu-Zanetti et al., 1999; Khurana et al., 2001; Souillac et al., 2003; Souillac 
et al., 2002a,b; Souillac et al., 2002b).  
Another link between thermodynamic stability and fibril formation is found in the recently 
analyzed I O18/O8 and 6a germline proteins.  These proteins were significantly more 
stable than all AL amyloidogenic proteins that have been studied to date (Baden et al., 
2008a; Del Pozo Yauner et al., 2008).  The Tm values (melting temperatures, at which 50% of 
the proteins are unfolded) for the germline proteins were increased by 15ºC and 11.6ºC, 
respectively, over the corresponding AL proteins analyzed in each study.  Both I O18/O8 
and 6a germline proteins had slower fibril formation kinetics than their amyloidogenic 
counterparts.  
Del Pozo Yauner and colleagues incorporated an R25G mutation into the 6a germline 
protein (6aJL2-R25G), as this mutation is found in 25% of amyloidogenic 6 LCs and 
presumably represents an allotypic variant (Ch'ang et al., 1994; del Pozo Yauner et al., 2006; 
Del Pozo Yauner et al., 2008).  This mutation resulted in a 6ºC decrease in Tm value for the 
mutated protein, and 6aJL2-R25G had a much shorter lag time and faster growth rate than 
the 6a germline protein.  The authors explain that the R25G mutation may affect the 
structure of complementarity determining region 1 (CDR1), resulting in an altered 
conformation and increased amyloidogenicity (del Pozo Yauner et al., 2006). 
Further research on the I O18/O8 germline protein and amyloidogenic AL-09 also 
connected thermodynamic stability to fibril formation.  Baden et al. undertook a 
systematic restorative mutational analysis of the non-conservative mutations of AL-09, 
which are all located in the dimer interface (Baden et al., 2008b).  Of the three non-
conservative restorative mutations (I34N, Q42K and H87Y), restoring the His87 mutation 
to the Tyr87 residue found in the germline sequence increased the thermodynamic 
stability and decreased the fibril formation kinetics to the same levels as I O18/O8.  
Significant structural alterations were also observed with this restorative mutant 
(discussed above, shown as a summary in Figure 2). Restoring the Asn34 residue had 
intermediate effects on stability and fibril formation propensity, while reintroducing 
Lys42 did not appear to alter the thermodynamics to any extent. 
In complementary experiments introducing the His87 residue from the amyloidogenic 
protein into I O18/O8, this protein was only destabilized half as much as AL-09.  I Y87H 
also had intermediate fibril formation kinetics between those measured for I O18/O8 and 
AL-09, indicating that this mutation alone may not have been sufficient for the 
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amyloidogenicity observed in AL-09.  However, introducing a second mutation into I 
O18/O8 (Ile34, in addition to His87) completely destabilized the protein and exhibited the 
same fast fibril kinetics as amyloidogenic AL-09.  Thus, rather than a single mutation that 
causes amyloidogenesis, it is probable that a combination of destabilizing and compensatory 
mutations leads to fibrillogenicity among AL proteins.  
 
 
Fig. 3. In restorative AL-09 and reciprocal κI mutants, rates of fibril formation are inversely 
correlated with ΔGfolding.  Mutation of Tyrosine 87 to Histidine stabilizes an altered dimer 
interface and leads to faster fibril formation. HSQC Analysis was used to identify each 
protein as single-state (green) or promiscuous (red) dimers; others were not determined 
(grey).  (Figure and legend adapted from (Peterson et al., 2010, Fig. 5), with permission of 
Elsevier. Copyright © 2010.) 
Other groups have studied fibril formation using different AL and MM proteins.  Jto, an 
MM protein, and Wil, an AL protein, are both light chain proteins from the 6a germline 
that differ by 19 amino acids. Fibrils were formed with both Jto and Wil at 37°C, pH 7.5 
(Wall et al., 1999). Jto fibrils appeared more rigid, were shorter and displayed slower 
kinetics than fibrils formed by Wil.  
Certain ionic interactions may affect fibrillogenesis and be crucial to maintain the structure 
and stability of LC proteins.  Wall et al. noted an ionic interaction between Asp29 and Arg68 
in MM protein Jto, whereas AL protein Wil has neutral amino acids in these positions (Wall 
et al., 2004). To test the importance of this ionic interaction, mutations were made to Jto to 
introduce the neutral residues (from Wil) at these sites (JtoD29A, JtoR68S).  The 
thermodynamic stabilities of these mutants were the same, and the rate of fibril formation 
for JtoD29A was the same as that for Jto.  However, fibril formation kinetics were much 
faster for JtoR68S, and an X-ray crystal structure of this mutant revealed several side-chain 
differences compared to Jto and JtoD29A.  These differences changed the electrostatic 
potential surface and increased the amount of solvent-exposed hydrophobic surface for the 
protein.  These results highlight critical structural features such as ionic interactions that 
participate in the stability and fibrillogenicity of AL proteins. 
Studies describing the properties of full length light chains from AL amyloidosis patients 
have been performed using both urine-derived proteins and recombinant full length 
www.intechopen.com
  
Amyloidosis – Mechanisms and Prospects for Therapy 
 
8 
constructs. The constant domain within the 6a protein AL-01-095 (CL belongs to LC3* 04) 
full length protein appears to confer great thermodynamic stability (Klimtchuk et al., 
2011), while the kappa unique CL does not play any role in the stability to the I O18/O8 
protein AL-09 (Olatoye, Levinson, and Ramirez-Alvarado, unpublished observations). 
Full length proteins isolated from urine samples from MM, Light Chain Deposition 
Disease (LCDD) and AL patients were studied to determine the type of aggregate formed 
by each type of protein.  Fibril formation reactions were followed at the Tm for each 
protein for 72 hours.  The results indicated that MM proteins formed spherical species, 
LCDD formed amorphous aggregates and AL proteins formed fibrils (Sikkink & Ramirez-
Alvarado, 2008a). Amyloid formation reactions with full length AL-09 and I O18/O8 
show slow rates of amyloid formation with respect to variable domain AL-09 and I 
O18/O8. The deposits found using electron microscopy show more disorder within the 
amyloid fibrils. These results suggest that the presence of the constant domain affects the 
misfolding pathway for these proteins. 
Collectively, these results have shown how the differences between LCs from AL 
amyloidosis patients (from different germline sequences and with different mutations) can 
determine the LC thermodynamic stability and fibril formation propensity.   
2.1.4 Effect of co-factors and protein modifications in amyloid formation reactions 
Amyloid fibril formation is initiated by the accumulation of oligomers to form a critical 
nucleus during the lag phase.  After nucleation, fibril growth occurs during the elongation 
phase. In addition to studying the characteristics that make a soluble LC protein more 
amyloidogenic, a tremendous amount of research has and is currently being done with 
respect to the factors that affect fibril formation in vitro.  These factors include temperature, 
pH, ionic strength, agitation, protein concentration, and pressure, which all destabilize the 
protein in order to populate partially folded states that are prone to aggregation (Chiti et al., 
1999). Each AL protein may be affected slightly differently by these co-factors (Figure 4). 
2.1.4.1 pH 
Experiments at various pH values showed differences between the AL and MM proteins. 
The rate of fibril formation for AL protein SMA was highly accelerated at pH 2 (Khurana et 
al., 2001). Both SMA and LEN formed fibrils at pH 2 with agitation, but SMA displayed 
faster kinetics (Khurana et al., 2003). Amorphous aggregation of SMA was observed in 
samples from pH 4 to 7, while fibrils were observed in samples at pH ≤3 implying that SMA 
formed different partially folded intermediates depending on the pH of the solution.  At pH 
4.5, 30 mM NaCl , SMA formed annular aggregates whereas at high ionic strength, fibrils 
and amorphous deposits were the predominant species (Zhu et al., 2004). At pH 7, the fibril 
formation kinetics of LEN was faster with lower protein concentrations and increased 
concentrations of urea (0 to 3 M) (Souillac et al., 2002a). 
Dye binding studies such as Thioflavine T fluorescence are commonly used to monitor fibril 
formation.  However, differentiating between different species formed during fibril 
formation is not possible with this method.  Thus, atomic force microscopy imaging was 
used to observe the evolution of different fibrillar species during a fibril formation reaction 
of SMA at pH 2; different filament sizes were found at different time points during the 
fibrillation.  A model was proposed where two filaments combine to form a protofibril and 
two protofibrils intertwine to form a type I fibril (Ionescu-Zanetti et al., 1999). 
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Fig. 4. The role of co-factors in amyloid formation: (A) amyloid formation reaction showing 
transition from native dimer structure to partially folded intermediate to amyloid fibrils  
(B) amyloid formation reaction accelerated by the presence of different co-factors. A 
common co-factor that accelerates fibril formation is low pH (high concentration of H+). 
2.1.4.2 Effect of the microenvironment: renal solutes, denaturants, protein concentration, 
and surfaces 
The use of renal solutes shed light onto the destabilizing and compensatory effects that 
different reagents can have on amyloid formation. Urea, a known protein denaturant, 
decreased the thermodynamic stability and the fibril formation kinetics of both SMA and 
LEN while betaine and sorbitol (organic osmolytes) had the opposite effect.  A concentration 
of 1.5 M urea was enough to increase fibril formation of both SMA and LEN (Kim et al., 
2001). Conversely, the presence of 0.5 M betaine or sorbitol partially inhibited SMA fibril 
formation showing the interplay between stabilizing and denaturing forces that may occur 
in physiological environments.  
Other denaturant studies indicate that SMA fibril formation kinetics were dependent on the 
concentration of guanidine hydrochloride (GdHCl) (Qin et al., 2007). The reaction at 2 M 
GdHCl had the fastest amyloid formation kinetics and the presence of fibrils was confirmed 
by electron microscopy, whereas amorphous aggregates were formed at lower 
concentrations of GdHCl.   Additionally, GdHCl affected the intermediate structures in fibril 
formation, determined by circular dichroism spectroscopy. At 1 M GdHCl, amorphous 
aggregates were formed by native-like intermediate structures, while at 2 M, amyloid fibrils 
were generated through an unfolded intermediate.  
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Protein concentration was another factor that influenced the fibril formation kinetics; low 
concentrations of LEN had faster kinetics of amyloid formation than higher concentrations 
(Souillac et al., 2002a,b). At high protein concentrations, LEN produced off-pathway 
oligomeric species before fibrils were formed (Souillac et al., 2003). At low protein 
concentrations, the off-pathway species were absent (Souillac et al., 2002b). Adding a “seed” 
of preformed fibrils to soluble protein solutions to trigger fibril growth also accelerated the 
kinetics of LEN fibril formation (Harper & Lansbury, 1997). The addition of 5% seeds in a 
SMA fibril formation reaction decreased the lag time by half when compared to an 
unseeded reaction (Davis et al., 2000).  
Zhu et al. studied the effect of surfaces on SMA amyloid fibril formation. (Zhu et al., 2002). 
They found that on mica surfaces, the rate of fibrillation was faster and the amount of 
protein required for the reaction decreased.  They also discovered different fibril growth 
mechanisms; on a mica surface, protofibrils were observed, while in solution, fibrils were 
present (Zhu et al., 2002). These surface experiments may be relevant in vivo since AL 
amyloid deposits are associated with the extracellular matrix in the basement membrane of 
tissues.  
In an effort to understand the role of components of the basement membrane where fibrils 
deposit, the role of lipids in amyloid formation for AL was recently reported.  The results 
indicated that a higher protein to lipid vesicles ratio slowed SMA amyloid formation 
kinetics (Meng et al., 2008). SMA fibrillation was affected by adding cholesterol to the lipid 
vesicles; specifically, cholesterol concentrations above 10% had an inhibitory effect.  
Additionally, in the presence of cholesterol and lipid vesicles, higher Ca2+ concentrations 
were shown to decrease SMA fibril formation kinetics The same effect was seen with Mg2+ 
and Zn2+ (Meng et al., 2008). This study suggests that amyloid deposition is influenced by 
the combined effects of cations and membrane surfaces.   
2.1.4.3 Hofmeister series 
One factor affecting fibril formation is the addition of salts or ions.  The Hofmeister series is 
a tool to understand salt ionic effects that ranks ions according to their ability to stabilize or 
destabilize a protein (Cacace et al., 1997; Zhang et al., 2005). A proof of principle study was 
done with the amyloidogenic VL protein AL-12 to determine the role of physiologically 
relevant anions and cations from the Hofmeister series on protein stability and amyloid 
fibril formation.  The presence of various salts with AL-12 did not affect the secondary 
structure of the protein (Sikkink & Ramirez-Alvarado, 2008b), and all salts enhanced 
amyloid formation. Reactions with SO42- and Mg2+ showed the largest enhancement of 
amyloid formation.  In addition, we recently performed a systematic analysis of the effect of 
different concentrations of NaCl on amyloid formation using two similar amyloidogenic 
light chains. AL-09 readily formed fibrils across a wide range of salt concentrations; 
however, the amyloidogenic light chain AL-103 (90% sequence identity to AL-09) showed a 
roughly inverse dependence of the fibril formation rate on salt concentration (Martin & 
Ramirez-Alvarado, 2010). These studies with various AL proteins and salts will help 
determine how sulfate ions enhance amyloid formation and will shed light onto the role of 
glycosaminoglycan sulfation on fibril formation in vivo.  
2.1.4.4 Glycosaminoglycans 
Glycosaminoglycans (GAGs) are a component of the extracellular matrix (Bosman & 
Stamenkovic, 2003) and have been found extensively in amyloid deposits.  They are long, 
www.intechopen.com
Current and New Perspectives on the Molecular and  
Cellular Mechanisms of Amyloid Formation and Toxicity in Light Chain Amyloidosis 
 
11 
unbranched, negatively charged heterogeneous polysaccharides formed by disaccharides of 
N-acetylglucosamine or N-acetylgalactosamine and uronic acid.  Ohishi et al. found that GAGs 
are an integral part of AL amyloid fibrils and that the level of GAGs increased 10-fold in 
tissues from amyloidosis patients, suggesting that GAGs not only play a role interacting with 
amyloid fibrils but the presence of the fibrils affect GAG levels (Ohishi et al., 1990). In vitro 
studies using HPLC chromatography and sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) showed an interaction between light chain proteins and various 
GAGs (Jiang et al., 1997). In another in vitro study, our laboratory showed that dermatan 
sulfate accelerated AL-09 amyloid fibril formation, whereas chondroitin sulfate A inhibited 
fibril formation and yielded a spherical intermediate (McLaughlin et al., 2006).  More recently, 
we have found that GAGs enhance amyloid formation by a transient electrostatic interaction 
with an early intermediate of the amyloid formation reaction (Martin & Ramirez-Alvarado, 
2011). 
Further studies of GAG influence on AL fibrillogenesis via the multiple sulfate moieties or 
its possible crowding effect on the amyloid fibril reaction may reveal important clues about 
the mechanism of amyloidogenesis and the role that GAGs play in the in vivo extracellular 
matrix deposition.   
2.1.4.5 Posttranslational modifications and oxidative stress 
Posttranslational modifications (PTMs) are also implicated in amyloidogenicity.  Of the 
amyloidogenic structural risk factors that Stevens identified in I light chains, N-
glycosylation was found in 22 of 121 samples, and 18 of those 22 samples were 
amyloidogenic (Stevens, 2000). None of the light chain germline genes encode a 
glycosylation site (N-x-S/T); thus, any putative glycosylation sites are introduced through 
somatic hypermutation.  Of the 18 amyloidogenic glycosylated LCs in Stevens study, most 
of them (13/18) also had other PTMs (including S-cysteinylation, fragmentation, 
dimerization and S-sulfonation), so a definitive role for glycosylation is difficult to 
delineate.  
Other studies also implicated glycosylation as an important characteristic among 
amyloidogenic proteins (Dwulet et al., 1986; Engvig et al., 1998; Foss et al., 1998; Omtvedt et 
al., 2000), and AL proteins were found to be glycosylated more frequently than circulating 
non-amyloidogenic free LCs (Holm et al., 1986; Omtvedt et al., 1997). Despite this evidence, 
the precise role of this PTM has yet to be determined.   
A more recent study of nine I light chains revealed several different PTMs in the full length 
LC proteins.  Each of the proteins studied had at least one type of PTM, and the range of PTMs 
included N-glycosylation, disulfide-linked dimerization, S-cysteinylation, fragmentation, S-
sulfonation, 3-chlorotyrosine formation, and conversion of aspartic acid to pyruvate (Connors 
et al., 2007). The exact relevance of these modifications to AL pathogenesis is unknown, but 
cysteinylation of other proteins was suggested to induce conformational changes (Chen et al., 
1999; Watarai et al., 2000), which could play a role in misfolding. Additionally, chlorotyrosine 
residues were linked to oxidative damage (Mohiuddin et al., 2006).  
Some PTMs found in AL proteins may actually have a protective role against 
amyloidogenesis. The two most heavily modified proteins in the aforementioned study 
(Connors et al., 2007) also included a methionine residue that had been oxidized to 
methionine sulfoxide.  Methionine and cysteine are the most easily oxidized amino acids, 
and oxidation of a methionine residue could protect other critical residues from damage by 
reactive oxygen species (ROS) (Levine et al., 2000). A study of MM protein LEN showed that 
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the methionine-oxidized form of the protein led to the formation of amorphous aggregates 
instead of fibrils (Hu et al., 2008). Thus, methionine oxidation may be part of a protective 
mechanism against amyloidogenic fibril formation for AL proteins.  However, because 
methionine oxidation is a fluctuating process, its antioxidant effect could be overcome by a 
preponderance of other amyloidogenic factors. 
Oxidation effects are particularly relevant to the study of AL proteins because oxidative 
stress has been linked both to amyloid fibril deposits and to the mechanism of cell death 
(Merlini & Westermark, 2004; Schubert et al., 1995). In a study by Ando and coworkers, AL 
amyloid deposits stained positively for 4-hydroxy-2-nonenal (HNE), a lipid peroxidation 
product indicative of oxidative injury (Ando et al., 1997). This result could not differentiate 
whether oxidative stress was involved in amyloid formation or if the fibrils triggered an 
oxidative stress reaction after deposition.  However, a more recent study indicated that 
oxidative stress caused by soluble amyloidogenic AL proteins plays a role in cell death.  
Brenner et al. examined the effects of cardiac AL proteins on cardiomyocytes and found that 
the presence of the amyloidogenic proteins caused an increase in intracellular reactive 
oxygen species and upregulation of a redox-sensitive protein (heme oxygenase-1) (Brenner 
et al., 2004). In addition, the contractility and relaxation of the cardiomyocytes was 
impaired, directly linking these soluble light chain proteins to cardiomyopathy in AL 
patients.   
Research is still being conducted to understand the mechanism of AL fibril formation and 
the role of co-factors and the cellular environment on amyloidogenicity.  It is important to 
expand on the currently reported work with additional AL proteins to find commonalities 
and differences of fibril formation properties for the different AL proteins.   
3. Tissue damage in AL amyloidosis-toxic effect of light chains 
The most important aspect of AL amyloidosis pathophysiology is the tissue damage 
associated with the process of amyloid formation. AL amyloidosis is a systemic protein 
misfolding disease; the site of deposition is distant from the site of protein synthesis and 
secretion (in this case, bone marrow plasma cells). While there have been some advances in 
cellular and tissue studies on the effect of light chains in cellular and tissue viability, what 
happens to the protein while in circulation is unknown. This aspect of the pathophysiology 
could only be studied with appropriate animal models.  
3.1 Cellular toxicity studies 
One of the most important questions in amyloidosis research is to determine the most toxic 
species of the amyloid formation reaction. For years, researchers assumed that the amyloid 
fibril deposits were highly toxic to the cells near them by blocking the exchange of nutrients, 
creating a mechanical barrier around the cells, and by attracting macrophages that 
ultimately caused tissue damage. Later on, experiments conducted with soluble fractions 
from preparations of amyloid affected tissue showed that soluble species were as toxic as or 
more toxic than insoluble amyloid fibrils. Recent work done by our laboratory and others 
has shown that the presence of soluble AL proteins in cell culture induces apoptosis (Shi et 
al., 2010; Sikkink & Ramirez-Alvarado, 2010). In particular, we were able to demonstrate 
that the light chain species present in cell culture at the time of maximum apoptotic activity 
are primarily light chain monomer and dimers.  
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Internalization studies using immunoglobulin light chain proteins have shown that full 
length AL-09 internalizes into cardiomyocytes within 24 h, migrating into lysosomal 
compartments and in certain instances, the nucleus (Figure 5). Full length I O18/O8 is 
delayed in this process. Single, restorative full length mutant AL-09 H87Y mimics the full 
length germline phenotype (Levinson, Olatoye, and Ramirez-Alvarado, unpublished 
observations). These studies are allowing us to fully characterize the biophysical, 
biochemical and cellular properties of amyloidogenic light chains to fully determine the 
role of somatic mutations in the disease process. These cellular internalization studies 
will reveal more details about the exact mechanism of toxicity by amyloidogenic light 
chains. 
 
 
Fig. 5. Proposed model of LC internalization, aggregation, and apoptosis showing 
internalization through endosomes (light grey) to lysosome (green) and nucleus (red) and 
removal of amyloid fibrils by exocytosis (dark grey). Amyloid fibril formation may happen 
intracellularly and could be later excreted into extracellular compartments. Alternatively, 
the process of cell death may allow fibrils to move to the extracellular matrix. 
3.2 Human tissue toxicity studies 
The first tissues affected by AL protein deposition are the blood vessels. It was previously 
shown that AL amyloidosis patients present with early endothelial microcirculatory 
dysfunction (Berghoff et al., 2003), and that light chain amyloid infiltration in epicardial 
coronary arteries occurs in almost all of the AL amyloidosis patients analyzed (Wittich et al., 
2007).  
Another report showed that the presence of light chain is associated with histological 
evidence of myocardial ischemia (decrease in the blood supply) in the majority of AL 
patients studied (Neben-Wittich et al., 2005). These findings suggest that microvascular 
dysfunction is central to AL pathophysiology, yet its underlying mechanism is unknown. 
Migrino et al. recently reported an increase in protein oxidation in AL amyloidosis patients. 
When arterioles were exposed to amyloidogenic light chains, they observed higher levels of 
superoxide and impaired dilation to sodium nitroprusside (Migrino et al., 2010). Human 
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arterioles are physiologically relevant to early AL pathophysiology and offer an important 
tissue system to study tissue dysfunction caused by AL light chains.  
3.3 Model systems 
Arendt and co-workers have established the first amyloidogenic human cell line system, 
ALMC-1 and ALMC-2 (Arendt et al., 2008). They used plasma cells from an AL patient 
isolated both pre- (ALMC-1) and post- (ALMC-2) stem cell transplant. These cell lines 
secrete a full length 6a LC protein called ALMC. While there is some genetic variation 
between ALMC-1 and ALMC-2, the protein sequences from both cell lines are 100% 
identical. The protein secreted from these cell lines was fully folded with a -sheet structure; 
it was as stable as other full length proteins (Sikkink & Ramirez-Alvarado, 2008a) and had 
the ability to form amyloid fibrils in vitro. These cell lines are a valuable tool because this is 
the only human-derived system that secretes a significant amount of protein for biophysical 
studies. We expect that future studies using these cell lines will advance our understanding 
of the cellular microenvironment and its possible role in the misfolding of light chain 
proteins.  
Currently, there is no reported animal model for AL amyloidosis that displays the full 
pathophysiology of the disease. An animal model attempt involved cloning and expression 
of amyloidogenic light chains using the cytomegalovirus (CMV) promoter. SP2/O Ig null 
plasmacytoma cell lines were stably transfected with the amyloidogenic light chain vectors 
and were transplanted into Balb/c and RAG mice, where they grew as plasmacytomas that 
secrete the amyloidogenic light chains. 4-6 weeks post transplant of these cells, human 
amyloidogenic light chains were found in the urine of the transfected animals. Some protein 
casts and granular deposits were found in the tubules of the kidneys of some of the 
transfected animals.  No Congo red staining (indicative of the presence of amyloid fibrils in 
tissues) was observed with these deposits. (Ward and coworkers abstract included in 
(Skinner et al., 2007)) 
Another animal model attempt involved creating a transgenic animal using the CMV 
promoter and bovine growth hormone polyadenylation signal. The expression of the 
transgenic protein was not ubiquitous, and the protein levels expressed were 1/10 of the 
levels found in the transplant model. Immunohistochemical analysis of different tissues 
showed the presence of the transgenic protein in the stomach gastric pit cells, the squamous 
epithelial cells of the bladder, the tubule cells in the kidney, in the cardiac cells and the 
pancreas. Congo red positive aggregation was observed in the lumen of the gastric glands of 
the stomach. The authors suggest that the low pH found in the stomach promoted amyloid 
formation of these amyloidogenic light chain after 4-6 months (Ward and coworkers abstract 
included in (Skinner et al., 2007)).  
More recently, Shi and co-workers reported an animal model in which wild type and 
dominant negative p38 transgenic mice were initially injected with amyloidogenic light 
chains through the tail vein followed by systemic intravenous infusion via the use of an 
osmotic minipump for 7 days. Wild type animals with fully active p38 presented an 
increase in the Bax/Bcl2 ratio and a very modest increase in cellular apoptosis as 
determined by TUNEL staining (Shi et al., 2010). 
Currently, none of the murine transgenic models of any of the systemic amyloidoses exhibit 
ideal characteristics to study the disease process. Buxbaum proposed that any future 
successful transgenic animal model of the extracellular amyloidoses should allow more 
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precise understanding of the pathogenesis and the role of other proteins in facilitating or 
inhibiting amyloid generation and deposition. The use of worms (Caenorhabditis elegans) and 
flies (Drosophila melanogaster) to study amyloidoses has allowed the study of some disease 
processes, but Buxbaum argued that the relationship between the cellular and molecular 
phenotype and human disease may be problematic (Buxbaum, 2009). 
4. How to ameliorate and eventually eliminate AL associated toxicity? 
Current treatments for AL amyloidosis target the malignant plasma cell population in bone 
marrow. These treatments are somewhat successful, whilst they are poorly tolerated by 
some AL amyloidosis patients. New therapeutic strategies targeting the amyloidogenic light 
chains and the AL amyloid fibrils are currently in development and their efficacies are being 
studied. 
4.1 Small molecules 
Small molecules have been tested in search of fibril formation inhibitors.  Congo red is a 
histological dye that binds to amyloid fibrils and presents a green birefringence under 
polarized light (Sipe & Cohen, 2000). AL-09 fibril formation was inhibited by Congo red at a 
1:1 molar ratio (McLaughlin et al., 2006). In contrast, Congo red did not inhibit fibril 
formation of SMA suggesting some specificity in the role of Congo red as an inhibitor (Kim 
et al., 2003). More research is needed to find effective fibril inhibitors for a variety of AL 
proteins both in vitro and using cell culture systems. 
4.2 Antibodies 
A murine monoclonal antibody (mAB 11-1F4) that binds to light chain fibrils but not soluble 
proteins was generated and characterized by Solomon and co-workers (O'Nuallain et al., 
2007; Solomon et al., 2003).  Immunohistochemical analysis revealed that mAB 11-1F4 
recognized light chain fibrils regardless of their VL subgroup.  The specificity of this 
antibody for AL fibrils (I, II, IV, 1, 3, 6, 8) was shown by Europium-Linked 
Immunosorbant Assay (EuLISA) where an EC50 value (concentration of antibody at half 
maximum binding) for binding was ~130 ± 39 nM (O'Nuallain et al., 2007).  The interaction 
of mAB 11-1F4 with native and fibrillar light chain LEN components was also checked by 
EuLISA and the antibody had similar avidity with both components.  However, the fibrils 
had a ~2 fold reduction in signal (O'Nuallain et al., 2007). Peptide mapping was used to 
determine the cryptic epitope; it is located in the first 18 amino acids of the variable light 
chain domain and a prolyl residue at position 8 is necessary.  A competition EuLISA was set 
up with mAB 11-1F4, and recombinant Wil fibrils were inhibited by a 50-fold molar excess 
of soluble LEN (1-22) peptide (O'Nuallain et al., 2007).  
4.3 siRNA 
A recent report has shown that small interference RNA (siRNA) can be used to reduce the 
amount of messenger RNA for amyloidogenic light chains. Phipps and co-workers 
transfected SP2/O mouse myeloma cells with a construct encoding the 6 AL light chain 
Wil under control of the cytomegalovirus promoter, using the l2-producing myeloma cell 
line RPMI 8226 as a control. The siRNA were designed specifically to the V, J, or C portions 
of the molecules. Forty eight hrs after exposure to the siRNAs, the authors observed 40% 
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reduction in messenger RNA and LC production with a greater effect observed in the 8226 
cells (Phipps et al., 2010). 
5. Conclusion  
Our knowledge of the molecular mechanisms of AL has greatly increased as a result of 
recent research about role of mutations, dimerization structures, different species populated 
in AL amyloid fibril formation, the cellular microenvironment, and light chain-associated 
cell and tissue toxicity. However, this complex disease is far from being understood, and 
each new discovery implicates other pathogenic factors, prompts additional questions, and 
reinforces the need for innovative research. In particular, the development of effective 
transgenic animal models and misfolding related therapeutic strategies, especially targeting 
light chain monomers and dimers, is necessary. A multidisciplinary research effort is 
required to analyze all aspects of the disease and provide a deeper understanding of its 
pathogenesis, ultimately leading to a successful therapeutic intervention. 
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